Nanoviricides, Inc. · AMEX:NNVC
Nanoviricides — Investor Presentation (December 2023)
25 slides from Nanoviricides's investor presentation, Dec 12, 2023
Slide 1: Bind-Encapsulate-Destroy
“Bind-Encapsulate-Destroy” Stock Symbol: NNVC (NYSE American) Nanoviricides, Inc. A Clinical Stage Company Revolutionizing Antiviral Therapeutics Platform Technology with Broad and Rich Pipeline Corporate Presentation as of December, 2023 Presented by: Anil R. Diwan, PhD President & Exec. Chairman a
Slide 2: Disclosure Statement
Disclosure Statement: NanoViricides, Inc. is a NYSE-American listed publicly traded company (NNVC). This is not an offering memorandum and should not be construed as such. This presentation is provided as a non-confidential document for informational purposes only. NanoViricides, Inc.(www.nanovirici
Slide 3: NanoViricides: At a Key Inflection Point; Ready for Take-off
NanoViricides : At a Key Inflection Point; Ready for Take-off Clinical Stage Company - NV-387, First Drug in Phase 1 Clinical Trials Nearing Completion Excellent Safety in Humans - No Adverse Events to Date Oral Syrup for Pediatrics, Oral Gummies (No swallowing) for Seniors and Adults Triple-demic i
Slide 4: How and Why Are NanoViricides Better Than Current Antiviral Drugs? Better by Design!
How and Why Are NanoViricides Better Than Current Antiviral Drugs? Better by Design! A Nanoviricide® is a Chemical Nanomachine that "Finds, Binds, & Engulfs” the Virus Particle so the Virus Cannot Reinfect Other Cells - Like a “Venus Flytrap” for Viruses It Does Not Require a Competent Immune System
Slide 5: Revolutionizing Treatment of Viral Infections Just As Antibiotics Revolutionized Bacterial Infections
Revolutionizing Treatment of Viral Infections Just As Antibiotics Revolutionized Bacterial Infections One Drug, NV-387, is Effective Against Many Respiratory Viruses Likely Most Effective Drug Against Coronaviruses - SARS-CoV-2 included Most Effective Against RSV - No Current Treatment Except Ribavi
Slide 6: Current Clinical Trial and Clinical-Ready Assets
Current Clinical Trial and Clinical-Ready Assets © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 6
Slide 7: Clinical Asset, NV-CoV-2 (NV-387): Phase I a/Ib Clinical Trial Near Completion
NanoViricides Drug Products : Clinical Asset, NV-CoV-2 (NV-387) Phase I a/Ib Clinical Trial Near Completion Orally Bio-available Drug; Two Oral Formulations in Clinical Trial NV-CoV-2 Oral Syrup (OS) - Titrate per Body Weight (Children) NV-CoV-2 Oral Gummies (OG) - Fixed Dose Form Oral Gummies to Ov
Slide 8: NV-CoV-2 (NV-387) Further Development Pathway - After Phase I
NanoViricides Drug Products : Clinical Asset, NV-CoV-2 (NV-387) Further Development Pathway - After Phase I Phase II or Phase II/III Clinical Trials for Different Antiviral Indications: 1. NV-CoV-2: Treatment of COVID and certain cases of Long COVID API NV-387, Oral Syrup and Oral Gummies Drug Produ
Slide 9: Clinical-Ready Assets NV-HHV-1 (Shingles) and NV-387-g-R
NanoViricides Drug Products : Clinical-Ready Assets NV-HHV-1 (Shingles) and NV-387-g-R (Broad-Spectrum Cure) NV-HHV-1: Skin Cream for Treatment of Shingles Rash IND-enabling Studies Completed NV-387-g-R: Encapsulates Remdesivir within NV-387; Eligible for Phase II Extremely Broad-Spectrum Antiviral,
Slide 10: Technology Platform, Technology Assets and Intellectual Property
NanoViricides Technology Platform, Technology Assets and Intellectual Property © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 10
Slide 11: ENABLER Platform Technology Asset: NanoViricides Technology Platform for Drug Development
NanoViricides ENABLER Platform Technology Asset: NanoViricides Technology Platform for Drug Development Build Drugs that Attack Virus Particles by Mimicking Attachment Factors Commonly Used by Many Virus Families (Platform Modality #1) NV-387 Mimicking S-PG Used by >90% Human Pathogens NV-x-458 Mimi
Slide 12: Technology Platform Enabling Expanding Pipeline: Encapsulation Into a Nanoviricide
NanoViricides Technology Platform Enabling Expanding Pipeline: Encapsulation of Another Drug Into a Nanoviricide - Potential Cures Complete Cure for Non-Latency Viruses A nanoviricide Can Hold in Its “Belly” and Deliver to Infected Cells, A Guest Drug The main Nanoviricide Blocks Re-Infection by Vir
Slide 13: ENABLER Platform: Cures Enabled, Drug Lifecycle Extension and Drug Rescue
NanoViricides ENABLER Platform Technology Asset: Cures Enabled while Providing Drug Lifecycle Extension and Drug Rescue by Encapsulation into a Nanoviricide The Nanoviricides Technology Platform is Proven to be Capable of Encapsulating and Protecting APIs Improving their PK/PD and Bioactivity, Enabl
Slide 14: Technology Differentiation
NanoViricides Technology Differentiation Nanoviricide Drug Antibodies Other Drugs Vaccines Re-Infection Replication Antibodies Mechanism Neutralization Inhibition Inhibition Generation Therapeutic Yes Yes Yes No Post-Infection? Viral Resistance Unlikely Rapidly Eventually Rapidly Cure Possible for Y
Slide 15: About NanoViricides, Inc. Intellectual Property
About NanoViricides, Inc. Intellectual Property Licensed Verticals of Programs from TheraCour Pharma, Inc. for Antiviral Drug Development Using the Unique TheraCour Polymeric Micelle Technology Licenses are for Vertical Areas - Treatment of Infections by Licensed Viruses Not Limited to Specific Drug
Slide 16: Value Proposition
NanoViricides Value Proposition © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 16
Slide 17: Value Proposition
NanoViricides Value Proposition Have Sufficient Funds to Support the Phase 1a/1b Clinical Trial of NV-CoV-2 Drug and Filing of Phase 2 Clinical Trial Application Own cGMP-Compliant Manufacturing Facility Assets estimated at Replacement Value in excess of $25 M No Debt or Mortgage Non-Dilutive Fundin
Slide 18: Why Is It Important that NanoViricides Owns Its Own cGMP-Capable Manufacturing Capability?
Why Is It Important that NanoViricides Designed & Owns Its Own cGMP-Capable Manufacturing Capability? Eliminate CMO Risks; Minimize Time & Costs of Drug Products for Phase 1, 2, & 3 Clinical Trials Manufacture Commercial Drug Products to Enable Early Revenues from Rapid Market Multi-Kg Scale Entry c
Slide 19: Technology Platform Enables Multiple Potential Revenue Sources to Finance Future Growth
NanoViricides Technology Platform Enables Multiple Potential Revenue Sources to Finance Future Growth Potential Drug Licensing to Big Pharma : NV-387 Clinical Stage; NV-HHV-1 (Same Platform) IND-Enabled Next Generation Drug (“Lifecycle Extension”) and “Drug Rescue” Opportunities for Big Pharma : Exa
Slide 20: Broad Pipeline Addressing Large Market Sizes to Fuel Continuing Growth
NanoViricides Broad Pipeline Addressing Large Market Sizes to Fuel Continuing Growth Into the Future NV-387, Clinical Stage Drug Several Billion Dollars Market Size for Coronaviruses Incl. SARS-CoV-2 and Long CoVID Existing Drugs Have Several Limitations $8 Billion Increasing to $20 Billion Estimate
Slide 21: Summary
Summary © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 21
Slide 22: Summary
Summary Clinical Stage Pharma Company with Unique Nanomedicines Platform Technology Revolutionary Approach Resulting in Highly Effective and Exceedingly Safe Drugs Fully Integrated Pharma Company with Its Own R&D Labs, Nanomedicine Characterization Labs and c-GMP-Compliant Manufacturing Facility, Cl
Slide 23: Strong Executive Team
Strong Executive Team Anil R. Diwan, PhD Krishna Menon, VMD, MRCS, PhD President & Exec. Chairman Consulting Pre-Clinical Studies Co-Founder 30+ Years of Pharmaceutical Industry Experience in Drug Led Uplisting to NYSE-American Exchange in 2013 Raised Over $100M Discovery and Pre-clinical Regulatory
Slide 24: Board of Directors
Board of Directors Anil R. Diwan, PhD Mak Jawadekar, PhD ✔ President & Exec. Chairman 35+ Years of Pharmaceutical Industry Experience, Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Co-Founder, Led Uplisting to NYSE-Amer
Slide 25: Together We Can Destroy Viruses
“Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Company, “NNVC” www.nanoviricides.com Together We Can Destroy Viruses Thank you for your attention. © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 25
NanoViricides — Investor Presentation (December 2023) on 6ix